PT - JOURNAL ARTICLE AU - Caruso, Giuseppe AU - Coleman, Robert L AU - Aletti, Giovanni AU - Multinu, Francesco AU - Botticelli, Andrea AU - Palaia, Innocenza AU - Cliby, William AU - Colombo, Nicoletta TI - Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon? AID - 10.1136/ijgc-2023-004740 DP - 2023 Sep 01 TA - International Journal of Gynecologic Cancer PG - 1448--1457 VI - 33 IP - 9 4099 - http://ijgc.bmj.com/content/33/9/1448.short 4100 - http://ijgc.bmj.com/content/33/9/1448.full SO - Int J Gynecol Cancer2023 Sep 01; 33 AB - Poly(ADP-ribose) polymerase inhibitors (PARPi) have sculpted the current landscape of advanced ovarian cancer treatment. With the advent of targeted maintenance therapies, improved survival rates have led to a timely interest in exploring de-intensified strategies with the goal of improving quality of life without compromising oncologic outcomes. The emerging concept of systemic treatment de-escalation would represent a new frontier in personalizing therapy in ovarian cancer. PARPi are so effective that properly selected patients treated with these agents might require less chemotherapy to achieve the same oncologic outcomes. The fundamental key is to limit de-escalation to a narrow subpopulation with favorable prognostic factors, such as patients with BRCA-mutated and/or homologous recombination-deficient tumors without macroscopic residual disease after surgery or other high-risk clinical factors. Potential de-escalation strategies include shifting PARPi in the neoadjuvant setting, de-escalating adjuvant chemotherapy after primary debulking surgery, reducing PARPi maintenance therapy duration, starting PARPi directly after interval debulking surgery, omitting maintenance therapy, and continuing PARPi beyond oligoprogression (if combined with locoregional treatment). Several ongoing trials are currently investigating the feasibility and safety of de-escalating approaches in ovarian cancer and the results are eagerly awaited. This review aims to discuss the current trends, drawbacks, and future perspectives regarding systemic treatment de-escalation in advanced ovarian cancer.